PT - JOURNAL ARTICLE AU - Leila Katirayi AU - Carl Stecker AU - Precious Andifasi AU - Angela Mushavi AU - Pradisha Tiwari AU - Chioniso Jakazi AU - Talent Maphosa AU - Viva Thorsen AU - Mildrate Murandu AU - Gladys Gombakomba AU - More Mungati AU - Lise Denoeud-Ndam AU - Emilia Rivadeneira AU - Rachel Weber AU - Susan Hrapcak TI - Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers’ and caregivers’ perspectives AID - 10.1136/bmjpo-2022-001474 DP - 2022 Jul 01 TA - BMJ Paediatrics Open PG - e001474 VI - 6 IP - 1 4099 - http://bmjpaedsopen.bmj.com/content/6/1/e001474.short 4100 - http://bmjpaedsopen.bmj.com/content/6/1/e001474.full SO - BMJ Paediatrics Open2022 Jul 01; 6 AB - Background In 2020, Zimbabwe adopted the WHO’s recommendation to use raltegravir (RAL) granule-based regimens for treatment of neonates identified with HIV at the time of birth testing. This study explores the acceptability of RAL granules by caregivers and healthcare workers (HCWs).Methods Interviews were conducted with 15 caregivers and 12 HCWs from 8 health facilities in Zimbabwe participating in the introductory pilot of RAL granules treatment for newborns. Eligible caregivers included those who had administered RAL to their infant and attended either 8th or 28th day of life appointments. Caregivers of neonates recently initiated on RAL were selected through convenience sampling. Eligible HCWs who provided RAL preparation, administration instructions and support to caregivers of neonates on RAL for at least 3 months were recruited from the same facilities as the caregivers. Interview transcripts were coded and thematically analysed.Results Caregivers reported that their babies looked healthier after RAL initiation, with improved skin appearance and weight gain. Some caregivers wanted their child to remain on RAL beyond 28 days instead of switching regimens, as recommended by national guidelines. HCWs observed that RAL granules improved health outcomes compared with other regimens. HCWs reported challenges with caregivers understanding dosing instructions, measuring with a syringe, swirling and not shaking the medicine, discarding unused medication and following the changes in the dosing schedule and amount when RAL was initiated a few days after birth. HCWs stated that adequate counselling and repeat demonstrations were crucial to ensure that caregivers clearly understood RAL dosing and administration instructions. HCWs requested more standardised training targeting nurses with guidance on handling missed doses and clarification on mixing RAL granules with water and not breastmilk.Conclusion While feedback from caregivers and HCWs on RAL implementation was positive, barriers were also noted. Adequate training and sufficient instruction and support for caregivers would help to ensure that RAL granules are prepared, dosed and administered correctly.Data are available upon reasonable request. Please contact the lead author to request data.